A complete substitute amendment. v2 entirely replaces v1's provisions, shifting the focus from specific limits on compounding commercially available drug copies and enhanced oversight/fees for outsourcing facilities to new reporting requirements for serious adverse events and interstate dispensing, alongside new labeling mandates for compounded drug products.
SAFE Drugs Act of 2026
- Sponsor
- Sen. Banks, Jim [R-IN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jul 27, 2026
Bottom line
This bill increases transparency and accountability for interstate compounded drug products by requiring adverse event and interstate dispensing reports, and by mandating specific consumer-facing labels.
What it actually does
The "SAFE Drugs Act of 2026," as reported with an amendment, primarily enhances federal and state oversight of drug compounding by licensed pharmacists and physicians who dispense products across state lines. It mandates reporting of serious adverse events associated with compounded drugs and requires annual reporting for those who send more than 5% of their compounded products out-of-state. Additionally, it introduces new labeling requirements for compounded drugs, including a disclaimer about FDA approval and information for adverse event reporting.
Proponents argue
Supporters argue that this bill is crucial for patient safety, as it provides federal and state regulators with vital data on adverse events and the volume of compounded drugs crossing state lines. They contend that the labeling requirements will better inform patients that compounded drugs are not FDA-approved, thereby managing expectations and promoting safer use. The information sharing system aims to streamline reporting, minimizing administrative burden while maximizing oversight.
Opponents contend
Critics might argue that the new reporting requirements, particularly the 5% interstate dispensing threshold, could impose undue administrative burdens on smaller compounding pharmacies and physicians, potentially limiting access to specialized compounded medications for patients in rural or underserved areas. They may also contend that the FDA disclaimer on labels could unnecessarily alarm patients about safe and legitimate compounded drugs.
The bill is concise and relatively easy to read, allowing a thorough understanding within the time typically allotted for legislative review.
Section 2(d)(1) of the amended Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a).
Mandatory Reporting of Serious Adverse Events for Interstate Compounded Drugs
This provision requires any licensed pharmacist or physician who compounds drugs and sends them across state lines to report any serious adverse events associated with those compounded drugs. These reports must be submitted to the FDA, the state where the compounding occurred, and all states where the drugs were sent, following existing FDA content and format guidelines. This ensures that potential safety issues are quickly communicated to relevant authorities.
Supporters argue
Supporters argue this is a critical patient safety measure, ensuring that potential harms from compounded drugs are promptly identified and addressed by regulators across all affected jurisdictions. It closes a potential information gap in oversight.
Critics contend
Some might argue that existing state-level reporting mechanisms are sufficient, and adding federal and multi-state reporting layers could create redundant or conflicting requirements, increasing administrative burden without a proportional increase in safety.
Tradeoffs
Balances the need for comprehensive safety oversight with the administrative burden on compounding practitioners.
Section 2(d)(2) of the amended Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a).
Annual Reporting for Significant Interstate Compounding Volume
Starting in 2027, any licensed pharmacist or physician who sends more than 5% of their total annual compounded drug products out of state must submit an annual report by January 15. This report must include the compounder's identifying information (name, address, license) and the total number of units of each type of compounded drug product sent to each applicable state, broken down by month. The FDA is tasked with creating an information sharing system to ease this reporting.
Section 3, amending Section 503A(b)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a(b)(3)).
Mandatory Disclaimer and Adverse Event Reporting Information on Compounded Drug Labels
This provision mandates that the label of any compounded drug product must include a clear statement: "This medication has been compounded for dispensing to an individual patients and has not been approved by the Food and Drug Administration." Additionally, it requires the inclusion of FDA contact information (website and phone number) for adverse event reporting. The Secretary may also prescribe other information to be included.
Mandates the Secretary to create an information sharing system to facilitate the transmission of interstate dispensing reports, aiming to reduce administrative burden.
Section 2(d)(2)(D) of the amended Federal Food, Drug, and Cosmetic Act.
Why it matters:Standard legislative practice to include administrative directives within substantive sections.
Case for: Proponents would highlight this as a commitment to efficiency, demonstrating an understanding of the administrative challenges faced by compounders and a proactive step to mitigate them.
Case against: No direct case against, but critics might question its effectiveness or implementation timeline.
Estimated impact: Potentially significant reduction in compliance costs for compounders if effectively implemented.
States that the federal reporting requirements do not preempt any State or political subdivision requirements for additional, more stringent, or supplementary reporting for compounded drug products.
Section 2(d)(3) of the amended Federal Food, Drug, and Cosmetic Act.
Why it matters:Standard legislative practice to clarify federal-state relations, but crucial for understanding the full regulatory landscape.
Case for: Proponents of state's rights and robust local oversight would support this, ensuring states can maintain or implement stricter patient safety measures if they deem necessary.
Case against: Those advocating for a uniform national standard might argue it could lead to a patchwork of regulations, increasing complexity for compounders operating in multiple states.
Estimated impact: Preserves state authority, potentially leading to varied regulatory environments across states.